Ryvu Therapeutics S.A. (WSE: RVU)
Health Care · Life Sciences Tools & Services · PL
zł18.40
+1.66% today · -38.4% 1Y
Ryvu Therapeutics S.A. (WSE: RVU) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $113.32M and employs 228 people.
Over the last twelve months the share price has lost 38.4%, trading between 13.64 and 31.90.
Tweenvest scores Ryvu Therapeutics S.A. across four factors: quality 37/100, value 60/100, growth 45/100. Its strongest factor is value.
RVU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $113.32M
- Revenue (TTM)
- $23.72M
- P/E
- —
- EPS
- -3.84
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- zł31.90
- 52-week low
- zł13.64
- Avg volume (3M)
- —
- Shares outstanding
- 23.12M
- Employees
- 228
- Next earnings
- —
About Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for development across hematological malignancies and solid tumors. This compound is presently in a Phase 1b clinical study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Among their other assets is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, which is currently undergoing a Phase 2 clinical trial for acute myeloid leukemia. Furthermore, Ryvu's earlier research pipeline explores candidates in areas such as kinases, cancer metabolism, synthetic lethality, and immuno-oncology. The company, established in 2007, is based in Kraków, Poland.
- ISIN
- PLSELVT00013
- Founded
- 2007
- Listed since
- Jul 14, 2011
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.26B | $628.15 | -0.09% |
| Danaher CorporationNYSE: DHR | $151.82B | $215.97 | +0.40% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $71.35B | CN¥161.00 | +3.31% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.65B | CHF593.80 | +1.02% |
| Agilent Technologies, Inc.NYSE: A | $43.71B | $154.77 | +0.87% |
| IQVIA Holdings Inc.NYSE: IQV | $42.70B | $259.42 | -0.32% |
| Waters CorporationNYSE: WAT | $40.72B | $414.44 | +0.90% |
Figures last refreshed Aug 18, 2026.